Perihilar Cholangiocarcinoma – Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers

Matteo Mueller(University Hospital of Zurich), Eva Breuer(University Hospital of Zurich), Takashi Mizuno(Nagoya University), F. Bartsch(Johannes Gutenberg University Mainz), Francesca Ratti(Vita-Salute San Raffaele University), Christian Benzing(Charité - Universitätsmedizin Berlin), Noémie Ammar-Khodja(Hôpital Paul-Brousse), Teiichi Sugiura(Shizuoka Cancer Center), Tsukasa Takayashiki(Chiba University), Amelia J. Hessheimer(Hospital Clínic de Barcelona), Hyung Sun Kim(Vita-Salute San Raffaele University), Andrea Ruzzenente(University of Verona), Keun Soo Ahn(Keimyung University), Tiffany Wong(Queen Mary Hospital), Jan Bednarsch(Universitätsklinikum Aachen), Mizelle D’Silva(Seoul National University Bundang Hospital), Bas Groot Koerkamp(Erasmus MC), Heithem Jeddou(Centre Hospitalier Universitaire de Rennes), Víctor López‐López(Hospital Universitario Virgen de la Arrixaca), Charles de Ponthaud(Hôpital Beaujon), Jennifer A. Yonkus(Mayo Clinic in Arizona), Warsan Ismail(Oslo University Hospital), Lynn E. Nooijen(Amsterdam University Medical Centers), Camila Hidalgo-Salinas(The Royal Free Hospital), Elissaios Kontis(King's College Hospital NHS Foundation Trust), Kim C. Wagner(Asklepios Klinik Barmbek), Ganesh Gunasekaran(Nagoya University), Ryota Higuchi(Johannes Gutenberg University Mainz), Ana Gleisner(Vita-Salute San Raffaele University), Chaya Shwaartz(University Health Network), Gonzalo Sapisochín(University Health Network), Richard D. Schulick(Vita-Salute San Raffaele University), Masakazu Yamamoto(Johannes Gutenberg University Mainz), Takehiro Noji(Hokkaido University), Satoshi Hirano(Hokkaido University), Myron Schwartz(Nagoya University), Karl J. Oldhafer(Asklepios Klinik Barmbek), Andreas Prachalias(King's College Hospital NHS Foundation Trust), Giuseppe Fusai(The Royal Free Hospital), Joris I. Erdmann(Amsterdam University Medical Centers), Pål‐Dag Line(Oslo University Hospital), Rory L. Smoot(Mayo Clinic in Arizona), Olivier Soubrane(Hôpital Beaujon), R Robles(Hospital Universitario Virgen de la Arrixaca), Karim Boudjéma(Centre Hospitalier Universitaire de Rennes), Wojciech G. Polak(Erasmus MC), Ho‐Seong Han(Seoul National University Bundang Hospital), Ulf P. Neumann(Universitätsklinikum Aachen), Chung‐Mau Lo(Queen Mary Hospital), Koo Jeong Kang(Keimyung University), Alfredo Guglielmi(University of Verona), Joon Seong Park(Vita-Salute San Raffaele University), Constantino Fondevila(Hospital Clínic de Barcelona), Masayuki Ohtsuka(Chiba University), Katsuhiko Uesaka(Shizuoka Cancer Center), René Adam(Hôpital Paul-Brousse), Johann Pratschke(Charité - Universitätsmedizin Berlin), Luca Aldrighetti(Vita-Salute San Raffaele University), Michelle Oliveira(University Hospital of Zurich), Gregory J. Gores(Mayo Clinic in Arizona), Hauke Lang(Johannes Gutenberg University Mainz), Masato Nagino(Nagoya University), Pierre‐Alain Clavien(University Hospital of Zurich)
Annals of Surgery
July 29, 2021
Cited by 172Open Access
Full Text

Abstract

OBJECTIVE: The aim of this study was to define robust benchmark values for the surgical treatment of perihilar cholangiocarcinomas (PHC) to enable unbiased comparisons. BACKGROUND: Despite ongoing efforts, postoperative mortality and morbidity remains high after complex liver surgery for PHC. Benchmark data of best achievable results in surgical PHC treatment are however still lacking. METHODS: This study analyzed consecutive patients undergoing major liver surgery for PHC in 24 high-volume centers in 3 continents over the recent 5-year period (2014-2018) with a minimum follow-up of 1 year in each patient. Benchmark patients were those operated at high-volume centers (≥50 cases during the study period) without the need for vascular reconstruction due to tumor invasion, or the presence of significant co-morbidities such as severe obesity (body mass index ≥35), diabetes, or cardiovascular diseases. Benchmark cutoff values were derived from the 75th or 25th percentile of the median values of all benchmark centers. RESULTS: Seven hundred eight (39%) of a total of 1829 consecutive patients qualified as benchmark cases. Benchmark cut-offs included: R0 resection ≥57%, postoperative liver failure (International Study Group of Liver Surgery): ≤35%; in-hospital and 3-month mortality rates ≤8% and ≤13%, respectively; 3-month grade 3 complications and the CCI: ≤70% and ≤30.5, respectively; bile leak-rate: ≤47% and 5-year overall survival of ≥39.7%. Centers operating mostly on complex cases disclosed better outcome including lower post-operative liver failure rates (4% vs 13%; P = 0.002). Centers from Asia disclosed better outcomes. CONCLUSION: Surgery for PHC remains associated with high morbidity and mortality with now the availability of benchmark values covering 21 outcome parameters, which may serve as key references for comparison in any future analyses of individuals, group of patients or centers.


Related Papers

No related papers found

Powered by citation graph analysis